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Abstract 1 
Background and purpose 2 
Primary prevention of stroke and transient ischaemic attack (TIA) is important to reduce the 3 
burden of these conditions; however, prescribing of prevention drugs is sub-optimal. We 4 
aimed to identify individual clinical and demographic characteristics associated with potential 5 
missed opportunities for prevention therapy with lipid-lowering, anticoagulant or 6 
antihypertensive drugs prior to stroke/TIA. 7 
Methods 8 
We analysed anonymised electronic primary care records from a United Kingdom (UK) 9 
primary care database that covers 561 family practices. Patients with first-ever stroke/TIA, 10 
≥18 years, with diagnosis between 1 January 2009 and 31 December 2013, were included.  11 
Missed opportunities for prevention were defined as people with clinical indications for lipid-12 
lowering, anticoagulant, or antihypertensive drugs but not prescribed these drugs prior to 13 
their stroke/TIA. Mixed-effect logistic regression models evaluated the relationship between 14 
missed opportunities and individual clinical/demographic characteristics. 15 
Results 16 
29,043 people with stroke/TIA met the inclusion criteria. Patients with Coronary Heart 17 
Disease, Chronic Kidney Disease, Peripheral Arterial Disease or diabetes were at less risk of 18 
a missed opportunity for prescription of lipid-lowering and antihypertensive drugs. However, 19 
patients with a 10-year CVD risk ≥20% but without these diagnoses had increased risk of 20 
having a missed opportunity for prescription of lipid-lowering drugs or antihypertensive 21 
drugs. Females were less likely to be prescribed anticoagulants but more likely to be 22 
prescribed antihypertensive drugs. The very elderly (≥85 years) were less likely to be 23 
prescribed all three prevention drugs, compared to people aged 75-79 years. 24 
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Conclusion 1 
Knowing the patient characteristics predictive of missed opportunities for stroke prevention 2 
may help primary care identify and appropriately manage these patients. Improving the 3 
management of these groups may reduce their risk and potentially prevent large numbers of 4 
future strokes and TIAs in the population. 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
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Introduction 1 
Stroke is a leading cause of death and disability worldwide; the Global Burden of Disease 2 
Study found stroke is the second leading cause of death1 and disability.2 Furthermore stroke 3 
incidence, in terms of absolute numbers, and age-adjusted prevalence rates have increased.3 4 
Therefore, primary prevention of stroke and transient ischaemic attack (TIA), a risk factor for 5 
stroke, is essential more than ever to reduce the burden of these conditions.  6 
Dyslipidaemia, atrial fibrillation (AF) and hypertension are modifiable risk factors for stroke 7 
which can be targeted through pharmacotherapy to reduce stroke risk.4-6 However, despite 8 
evidence-based guidelines, prescribing of lipid-lowering, anticoagulant and antihypertensive 9 
drugs for primary stroke/TIA prevention is suboptimal in primary care. We previously found 10 
that over half of people eligible for one or more of these drugs were not prescribed them prior 11 
to first stroke/TIA.7 Approximately 12,000 first-strokes could potentially be prevented 12 
annually in the United Kingdom (UK) through optimal prescribing of lipid-lowering, 13 
anticoagulant and antihypertensive drugs.7 14 
A number of studies suggest variations and inequalities in prescribing of lipid-lowering, 15 
anticoagulant and antihypertensive drugs for prevention of cardiovascular disease (CVD).8-14 16 
There are inconsistent findings regarding the association between deprivation status and 17 
prescribing of prevention drugs;10, 13 a Scottish study found that more deprived people were 18 
less likely to be prescribed statins,11 whereas as a survey of English family practices found 19 
higher prescriptions of statins in more deprived areas.9 Sex differences have also been 20 
observed; a survey of hypertension treatment in Europe and North America found women 21 
were more likely than men to be prescribed antihypertensive drugs.14 Conversely, French and 22 
Japanese studies reported women were less likely to be prescribed anticoagulant drugs.8,12 23 
However, these studies did not consider prescribing practice in the context of predicted CVD 24 
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and stroke risk and clinical indications for prescribing. This is important because a treatment-1 
risk paradox has been observed whereby there is overprescribing of prevention drugs in 2 
people without a clinical indication13 and sub-optimal prescribing in people at high risk.15 3 
Understanding what characteristics are associated with sub-optimal prescribing of prevention 4 
drugs in eligible patients is important to improve primary prevention of stroke/TIA. 5 
Our objective was to determine the relationship between clinical and demographic 6 
characteristics and prescription of lipid-lowering, anticoagulant or antihypertensive drugs in 7 
patients with clinical indications prior to stroke/TIA. 8 
Methods 9 
The full protocol for this study has been published elsewhere,16 methods are summarised in 10 
brief below. The data that support the findings of this study are available from the 11 
corresponding author upon reasonable request. 12 
Study design and data source 13 
We conducted a retrospective analysis of electronic medical records from 561 family 14 
practices in the UK. Anonymised data were obtained from The Health Improvement Network 15 
(THIN),17 a large primary care database which covers approximately 6% of the UK 16 
population and is broadly generalisable in terms of age, sex and morbidity.18 Recording of 17 
stroke and TIA in THIN have a high validity.19 Furthermore, prescribing data are 18 
comprehensive and accurate because this data is automatically retained in patients’ electronic 19 
medical records from software used to print prescriptions.20 20 
Analysis of THIN data has ethical approval from the National Health Service South-East 21 
Multicentre Research Ethics Committee, subject to independent scientific review.21 This 22 
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study had approval by a scientific review committee administered by IMS Health Real-World 1 
Evidence Solutions (reference: 13-023). 2 
Population 3 
We defined primary stroke prevention as prevention of stroke in individuals with no prior 4 
history of stroke; therefore, the study population comprised patients with a diagnosis of first 5 
stroke (with or without previous TIA) and first TIA (if no prior stroke). Patients were 6 
included who had a stroke/TIA diagnosis between 1 January 2009 and 31 December 2013 7 
and were aged ≥18 years at their diagnosis. The date of first-ever stroke or TIA was taken as 8 
the index date.  9 
Definitions of missed opportunities for primary stroke/TIA prevention 10 
A potential missed opportunity for stroke/TIA prevention was defined as a person in whom a 11 
prevention drug was clinically indicated at the time of their stroke or TIA, but who was not 12 
receiving treatment. This meant no prescription of a lipid-lowering or antihypertensive drug 13 
within the previous 90 days (the usual maximum prescription length in the UK) or for an 14 
anticoagulant drug within 120 days (to allow for referral to an anticoagulation clinic). 15 
Patients with a clinical code for anticoagulation monitoring were also considered to be on 16 
anticoagulant drugs.  17 
The most recent risk factor data prior to the stroke/TIA were used to determine if stroke 18 
prevention drugs were clinically indicated. Clinical indications for lipid-lowering, 19 
anticoagulant, and antihypertensive drugs were based on UK national guidelines used during 20 
the study period (Online supplement).5,22,23  21 
Analysis 22 
All analysis was conducted using STATA version 12 (StataCorp). The relationship between 23 
clinical/demographic characteristics (Online supplement) and missed prescribing 24 
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opportunities was evaluated using mixed-effects logistic regression, with family practice as a 1 
random effect and odds ratios (OR) reported. Age and sex were forced into the models 2 
because they were pre-identified as important predictors of under-treatment.24-26 Year of 3 
stroke/TIA was included as a covariate in the regression models. Backwards elimination with 4 
a p-to-eliminate value of >0.05 was used to select variables to be included in the final 5 
models. Exploratory analyses are detailed in the online supplement. No attempt was made to 6 
impute missing data, but a “missing” category was created for categorical variables. 7 
 8 
Results 9 
29,043 people with stroke/TIA met the inclusion criteria (Table 1). The median age was 74 10 
years (IQR 64,82) and 51% were female. 17,680 patients had a clinical indication for one or 11 
more stroke prevention drugs, of which, 9,579 were not prescribed these drugs at the time of 12 
their stroke or TIA. Missed opportunities for prescribing of prevention drugs was found in 13 
49% (7,836/16,028) of patients with a clinical indication for lipid-lowering drugs, 52% 14 
(1,647/3,194) for anticoagulant drugs and 25% (1,740/7,008) for antihypertensive drugs.7 15 
Predictors of missed opportunities for prescription of prevention drugs 16 
The adjusted ORs for each prevention drug are presented below and reported in eTables I-III. 17 
Sex 18 
Females had increased odds of having a missed opportunity for prescribing anticoagulant 19 
drugs (OR 1.37; 95% CI 1.18,1.58); however, the opposite was true for antihypertensive 20 
drugs (OR 0.85; 95% 0.74,0.97) and there was no sex effect for lipid-lowering drugs. 21 
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Age 1 
The very elderly (≥85 years) had increased odds of not being prescribed lipid-lowering, 2 
anticoagulant and antihypertensive drugs when clinically indicated (eTables I-III). For lipid-3 
lowering and antihypertensive drugs, there was a J-shaped relationship between age and 4 
missed prescribing opportunities where younger age categories (50-69 years) also had 5 
increased odds of missed opportunities (reference category 75-79 years; eTables I and III). 6 
However, for anticoagulant drugs, patients between 55 to 59 years had reduced odds of 7 
having a missed opportunity (eTable II). 8 
Comorbidities 9 
The odds of missed opportunities for lipid-lowering drug prescribing were less than a third in 10 
stroke/TIA patients with a diagnosis of coronary heart disease (CHD) (OR 0.21; 95% CI 11 
0.19,0.22) or diabetes (OR 0.31; 95% CI 0.28,0.33) and significantly reduced in patients with 12 
a diagnosis of peripheral arterial disease (PAD) (OR 0.52; 95% CI 0.45,0.60), hypertension 13 
(OR 0.69; 95% CI 0.64,0.75) or chronic kidney disease (CKD) (OR 0.86; 95% CI 0.79,0.94).  14 
For antihypertensive drugs, odds of having a missed opportunity were substantially lower in 15 
patients with a diagnosis of hypertension (OR 0.09; 95% CI 0.07,0.11), CHD (OR 0.26; 95% 16 
CI 0.21,0.33), AF (OR 0.35; 95% CI 0.27,0.47), diabetes (OR 0.43; 95% CI 0.35,0.52), heart 17 
failure (OR 0.49; 95% CI 0.33,0.73) and CKD (OR 0.50; 95% CI 0.41,0.60). In addition, 18 
significantly reduced odds of having a missed opportunity for a prescription for 19 
antihypertensive drugs was found for patients with a diagnosis of PAD (OR 0.62; 95% CI 20 
0.47,0.81), cancer (OR 0.78; 95% CI 0.62,0.98), hypothyroidism (OR 0.79; 95% CI 21 
0.63,1.00) or asthma (OR 0.79; 95% CI 0.62,1.00). For anticoagulant drugs, a diagnosis of 22 
heart failure (OR 0.53; 95% CI 0.44,0.63) or diabetes (OR 0.82; 95% CI 0.69,0.98) was 23 
associated with reduced odds of having a missed opportunity for prescribing of these drugs. 24 
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Increased odds of having a missed opportunity was associated with a diagnosis of dementia 1 
for anticoagulant (OR 1.51; 95% CI 1.11,2.06) and antihypertensive drugs (OR 1.78; 95% CI 2 
1.26,2.51); palliative care (OR 2.48; 95% CI 1.83,3.34) for lipid-lowering drugs; and number 3 
of comorbidities (OR 1.28 per unit increase; 95% CI 1.16,1.42) for antihypertensive drugs. 4 
There was no association between number of comorbidities and prescribing of lipid-lowering 5 
or anticoagulant drugs.  6 
CVD risk 7 
Exploratory analyses (Online supplement) found that people with a 10-year CVD risk ≥20% 8 
but without ‘high risk comorbidities’ (CHD, CKD, PAD, diabetes or familial 9 
hypercholesterolaemia) had a 3-fold increased odds having a missed opportunity for lipid-10 
lowering drug prescribing (OR 2.81; 95% CI 2.47,3.21). There were 2,780 patients with a 11 
clinical indication for lipid-lowering drugs who had a 10-year CVD risk ≥20% but no high 12 
risk comorbidities; 81% (2,238/2,780) of these were not prescribed these drugs. Similarly, 13 
patients with a clinical indication for antihypertensive drugs who had a 10-year CVD risk 14 
≥20% but no ‘high risk comorbidities’ had increased odds of having a missed opportunity for 15 
these drugs (OR 1.43; 95% CI 1.17,1.75). There were 1,076 of these patients eligible for 16 
antihypertensive drugs due to a 10-year CVD risk ≥20% but no ‘high risk comorbidities’; 17 
45% (479/1,076) were not prescribed these drugs. 18 
Behavioural and other demographic characteristics 19 
After adjustment for clinical and other patient factors, current smokers and people with a 20 
missing smoking status were more likely to have a missed opportunity for prescription of 21 
lipid-lowering and anticoagulant drugs, compared to non-smokers (eTable I and II). 22 
Stroke/TIA patients who were underweight (body mass index [BMI] <18.5 kg/m2) or missing 23 
BMI had increased odds of not being prescribed lipid-lowering and anticoagulant drugs, 24 
compared to people with a healthy BMI (18.5-25.9 kg/m2) (eTable I and II). Being 25 
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overweight (BMI 26.0-30.0 kg/m2) or obese (BMI >30.0 kg/m2) was associated with 1 
increased odds of having a missed opportunity for anticoagulant drugs, but reduced odds for 2 
lipid-lowering drugs (eTable I and II). There was no association between BMI or smoking 3 
and antihypertensive prescribing. 4 
Provision of lifestyle advice was associated with reduced odds of missed opportunities for 5 
prescribing lipid-lowering drugs (advice on smoking and weight) and antihypertensive drugs 6 
(advice on weight; eTables I and III). There were statistically significant regional differences 7 
for prescribing of lipid-lowering drugs with stroke/TIA patients in Wales (OR 0.72; 95% CI 8 
0.59,0.89) and Northern Ireland (OR 0.72; 95% CI 0.59,0.88) more likely to be prescribed 9 
these drugs (West Midlands region of England as reference). 10 
Deprivation and rurality (urban/rural) status had no effect on missed prescribing opportunities 11 
for any of the three prevention drugs.  12 
 13 
Discussion 14 
Principal findings 15 
We identified population subgroups where there are potential missed opportunities for 16 
prevention of stroke/TIA. Females were less likely to be prescribed anticoagulants but more 17 
likely to be prescribed antihypertensive drugs; however, there was no sex effect for lipid-18 
lowering drugs. Compared to patients aged 75-79 years, the very elderly (≥85 years) and 19 
patients aged 50-69 years were less likely to be prescribed preventative drugs. Patients on a 20 
disease register for CHD, CKD, PAD or diabetes were markedly more likely to be prescribed 21 
lipid-lowering and antihypertensive drugs. In contrast, patients at high risk (i.e. with a 10 year 22 
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CVD risk ≥20%) but not on these disease registers were much less likely to be prescribed 1 
these drugs. Deprivation and urban/rural status had no effect on prescribing. 2 
Strengths and weaknesses of the study 3 
The strengths of this study are that the data source is generalisable to UK family practices and 4 
reflects routine clinical practice. Prescribing data are accurate and comprehensively 5 
recorded27 and the sample size is very large. Stroke and the main comorbidities are likely to 6 
be accurately recorded as they are clinically significant; diagnoses have been validated within 7 
THIN;19 and, in the UK, GPs are incentivised through QOF to keep a register of patients with 8 
these conditions.  9 
This was an epidemiological, descriptive study; therefore, an important limitation is that the 10 
reasons for non-prescribing are unclear. There may be legitimate reasons why patients were 11 
not prescribed preventative medication which are not routinely coded in electronic patient 12 
records, such as patients’ preference, limited life expectancy or increased bleeding risk (when 13 
prescribing anticoagulant drugs). Clinical judgment should be used in combination with 14 
patient preference when considering prescribing preventative medication. Therefore, non-15 
prescribing of these drugs should not be considered a missed opportunity if the doctor and 16 
patient have engaged in a shared decision making process incorporating the best available 17 
evidence. Patients with clinical codes indicating prevention drugs were declined, 18 
contraindicated or an adverse reaction were not excluded from the analysis because it is 19 
unclear if these were relevant at the time of index stroke/TIA. The number of patients in our 20 
sample with these codes was small (5%, 7% and 0.7% for lipid lowering, anticoagulant and 21 
antihypertensive drugs, respectively), suggesting that this information would not have altered 22 
our conclusions. Lastly, prevention of stroke/TIA is complex and our definition of missed 23 
prescribing opportunities does not address patients’ adherence to medication, appropriate 24 
prescribing of drug combinations or medication targets, such as blood pressure levels. 25 
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Implications for clinical practice 1 
The relationship we identified between sex and prescribing of preventative drugs has 2 
important clinical implications, particularly for anticoagulant drugs. Female sex is an 3 
independent risk factor for stroke in AF patients and strokes in women with AF are 4 
associated with increased mortality and disability compared to males.28,29 Therefore, sub-5 
optimal prescribing of anticoagulants in females is likely to have a large impact on the burden 6 
of stroke. Bleeding risk has been cited as the most common reason for physicians not 7 
prescribing anticoagulants30 and some evidence suggests that bleeding risk is greater in 8 
women.31 However, a recent systematic review found no difference in risk of bleeding 9 
between men and women.32 Anticoagulation in AF patients with the highest stroke risk is 10 
likely to provide the greatest benefit; therefore, raising clinicians’ awareness of sub-optimal 11 
prescribing of anticoagulants in females and the associated burden has potential to improve 12 
stroke prevention in these high-risk patients. 13 
Missed opportunities for stroke prevention in patients with a high 10-year CVD risk may 14 
suggest that absolute risk is not considered. This is supported by our finding that patients with 15 
a diagnosis of CHD, CKD, PAD or diabetes were more likely to be prescribed lipid-lowering 16 
and antihypertensive drugs while those without these diagnoses but with a high 10-year CVD 17 
risk were less likely to be prescribed these drugs. Our study calculated patients’ CVD risk 18 
scores post-hoc; however, many of the patients may not have had their CVD risk calculated 19 
by GPs. A survey of physicians from six European countries found that only 38% used risk 20 
scores to estimate CVD risk.33 This has important implications because evidence suggests 21 
that both patients34 and clinicians35,36 underestimate CVD risk. This is particularly relevant 22 
following the most recent guideline recommendations for lipid-lowering drug prescribing 23 
which decrease the 10-year CVD risk cut off from ≥20% to ≥10%.4 Furthermore, perception 24 
of risk is influenced by social context, such as the media.37 A study of UK primary care found 25 
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that a period of intense media coverage on statins was associated with a decrease in recording 1 
of CVD risk scores and increase in the number of people who stopped taking statins.38 The 2 
responsibility of GPs to accurately assess absolute CVD risk and effectively communicate 3 
this risk is essential to inform the shared decision making process and prevent patients 4 
missing out on preventative medication that they may benefit from and wish to take.39  5 
Presence of a single comorbidity was associated with with reduced odds of having a missed 6 
opportunity for prescribing antihypertensives; however, an increased number of 7 
comorbidities increased the odds of having a missed opportunity for these drugs (eTable III). 8 
Prescribing of antihypertensives in patients with a single comorbidity may be higher because 9 
in UK primary care general practices are incentivised to include these patients on a disease 10 
register and regularly follow them up. This increases the opportunities for detection and 11 
treatment of hypertesnsion. The reseaon for underprescribing of antihypertensive drugs in 12 
people with multimorbidity is unclear; however, it could be reflective of documented barriers 13 
to antihypertensive drug, which include: hypertension not considered a clinical priority,40 14 
compteting medical problems,41 polypharmacy25 and physicians lack of belief of the benefit 15 
of these drugs.25 Inadequate blood pressure control in people with multi morbidity has been 16 
observed in the literature.42 17 
Missed opportunities to prescribing prevention drugs to the very elderly has important 18 
implications because age is one of the most important risk factors for stroke/TIA and the 19 
population is ageing.43 In particular, this is relevant for anticoagulant prescribing where 39% 20 
(1,240/3,194) of stroke/TIA patients with these drugs clinically indicated were aged ≥85 21 
years, compared to 21% (3,368/16,028) and 22% (1,538/7,008) for lipid-lowering and 22 
antihypertensive drugs respectively. There is a lot of potential gain in this elderly patient 23 
group; the net benefit of anticoagulation is greatest in the elderly and the benefits of 24 
anticoagulation in the elderly have been shown to outweigh the risk.44  25 
14 
 
Current lipid-lowering guidelines recommend all patients aged ≥85 years are considered high 1 
risk4 and hypertension guidelines recommend people aged >80 years are prescribed the same 2 
antihypertensives as patients aged 55-80 years.5 However, the guidelines acknowledge that 3 
there is a lack of evidence to support these recommendations,4,5 particularly for stroke 4 
prevention. Furthermore, there are greater risks for prescribing prevention drugs to the very 5 
elderly in the context of multimorbidity and polypharmacy. The benefit of preventative 6 
medication may be redundant if a patient has reduced life expectancy, frailty or the treatment 7 
burden is greater than the added length or quality of life.45 Multimorbidity guidelines 8 
recommend that prescribing of preventative medication should take a personalised approach 9 
and include patients’ preferences and health priorities.45 Therefore, age alone should not 10 
preclude prescribing of prevention drugs, but prescribing of these drugs should be undertaken 11 
using shared decision making in consideration of the best available evidence, treatment 12 
burden and patients’ preference. 13 
Conclusions  14 
Stroke can be preventable; however, opportunities for prevention may be missed. We 15 
identified characteristics that are associated with missed prescribing opportunities for lipid-16 
lowering, anticoagulant and antihypertensive drugs. Patients with a high calculated CVD risk 17 
but who did not have high risk comorbidities were markedly less likely to be prescribed lipid-18 
lowering and antihypertensive drugs. In addition, female patients with AF were less likely to 19 
be prescribed anticoagulant drugs and people aged ≥85 years were less likely to be prescribed 20 
all three prevention drugs. Despite evidence-based guidelines, prevention of stroke and TIA 21 
with pharmacotherapy remains suboptimal in primary care. Knowledge of patient 22 
characteristics associated with missed opportunities for prescribing of prevention drugs 23 
15 
 
provides an opportunity to raise awareness amongst clinicians and improve primary 1 
prevention of stroke/TIA. 2 
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Tables 1 
Table 1: Characteristics of the study population. 2 
Diagnosis (n,%) Stroke only 16,245 (55.9) 
 TIA only 10,446 (36.0) 
 Stroke with previous TIA 2,352 (8.1) 
Age (Median [IQR]) (years) 74 [64, 82] 
Sex (n,%) Male 14,204 (48.9) 
  Female 14,839 (51.1) 
Comorbidity (n,%) Atrial fibrillation 3,544 (12.2) 
 Asthma 3,062 (10.5) 
 Cancer 3,239 (11.2) 
 CHD 5,543 (19.1) 
 CKD 5,774 (19.9) 
 COPD 2,198 (7.6) 
 Dementia 1,270 (4.4) 
 Depression 6,174 (21.3) 
 Diabetes 4,512 (15.5) 
 Epilepsy 614 (2.1) 
 Heart failure 1,625 (5.6) 
 Hypertension 14,646 (50.4) 
 Hypothyroidism 2,890 (10.0) 
 Learning disability 130 (0.5) 
 Osteoporosis 2,318 (8.0) 
 PAD 1,431 (4.9) 
 Palliative care 359 (1.2) 
 Psychosis 439 (1.5) 
  Rheumatoid arthritis 655 (2.3) 
CHD: Coronary Heart Disease, CKD: Chronic Kidney Disease, COPD: 
Chronic Obstructive Pulmonary Disease, PAD: Peripheral Artery 
Disease, TIA: Transient Ischaemic Attack 
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